# 10x Genomics, Inc.  Share Price Target ‘$39.69’, now 111.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.share-price-target-39.69-now-111.7-upside-potential/4121163931
- Published: 2024-07-05T16:28:24+01:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** which can be found using ticker (TXG) now have 13 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $55.00 and $
24.00 and has a mean share price target at $39.69. (at the time of writing). Given
that the stocks previous close was at $18.75 this is indicating there is a potential
upside of 111.7%. The 50 day moving average now sits at $23.34 and the 200 day moving
average is $37.77. The company has a market capitalization of 2.22B. The stock price
for the company is currently $18.54 USD

 The potential market cap would be $4,698,352,009 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.30 and
a -13.06% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: